Although PD-1/PD-L1 levels are elevated in AML individuals, AML treatment with PD-1/PD-L1 inhibitors is associated with a significant risk of relapse in prognosis, and does not eliminate the possibility of inducing other neoplastic conditions. The gene discussed is CD274; the disease is acute myeloid leukemia.